regn7075
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 23, 2020 (NCT04626635)
Timeline
Indications
Mechanism of action
CD28 inhibitor
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281768 | Phase 2 | Mar 31, 2026 | Johns Hopkins University, Regeneron |
| NCT07154290 | Phase 2 | Jan 26, 2026 | Regeneron |
| NCT07058012 | Phase 2 | Aug 1, 2025 | NSABP Foundation, Regeneron |
| NCT06465329 | Phase 2 | Nov 15, 2024 | Regeneron |
| NCT04626635 | Phase 1/Phase 2 (Phase 2) | Dec 23, 2020 | Regeneron |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 5 | 3 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| NSABP Foundation | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1